Last reviewed · How we verify

SM03 — Competitive Intelligence Brief

SM03 (SM03) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD40 ligand inhibitor (monoclonal antibody). Area: Immunology.

phase 3 CD40 ligand inhibitor (monoclonal antibody) CD40L (CD154) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

SM03 (SM03) — SinoMab BioScience Ltd. SM03 is a monoclonal antibody that targets CD40 ligand (CD40L) to modulate immune responses and reduce inflammatory activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SM03 TARGET SM03 SinoMab BioScience Ltd phase 3 CD40 ligand inhibitor (monoclonal antibody) CD40L (CD154)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD40 ligand inhibitor (monoclonal antibody) class)

  1. SinoMab BioScience Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SM03 — Competitive Intelligence Brief. https://druglandscape.com/ci/sm03. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: